Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Allurion Technologies, Inc. Common Stock (NY:ALUR)

1.000 -0.350 (-25.93%)
Streaming Delayed Price Updated: 1:36 PM EST, Feb 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Allurion Technologies, Inc. Common Stock

< Previous 1 2 3 4 Next >
News headline image
Allurion Announces Partnership to Offer Combination Therapy with Mounjaro® (tirzepatide) at Discounted Prices
From Allurion Technologies, Inc.
Via Business Wire
News headline image
Allurion Announces Preliminary Fourth Quarter and Full-Year 2025 Results
From Allurion Technologies, Inc.
Via Business Wire
News headline image
Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 Adherence
From Allurion Technologies, Inc.
Via Business Wire
News headline image
New Peer-Reviewed Publication Demonstrates Superior Weight Loss and Improved Body Composition with the Allurion Smart Capsule Combined with Lifestyle Intervention Compared to Lifestyle Intervention Alone
From Allurion Technologies, Inc.
Via Business Wire
News headline image
Allurion Announces Strategic Distribution Partnership with ProSurg Medical in Brazil to Pioneer New Approach Focused on Metabolically Healthy Weight Loss
From Allurion Technologies, Inc.
Via Business Wire
News headline image
Allurion Reports Third Quarter 2025 Financial Results and Provides Business Update
From Allurion Technologies, Inc.
Via Business Wire
News headline image
Allurion Passes Critical FDA Milestones, Enters Into Transaction to Exchange All Outstanding Debt That Would Result in the Company Being Debt-Free, and Announces a $5 Million Private Placement Financing
From Allurion Technologies, Inc.
Via Business Wire
News headline image
Allurion to Report Third Quarter 2025 Financial Results on November 12, 2025
From Allurion Technologies, Inc.
Via Business Wire
News headline image
Allurion Announces Landmark Peer-Reviewed Publication on Consecutive Use of the Allurion Smart Capsule Showing More Than 20% Weight Loss
From Allurion Technologies, Inc.
Via Business Wire
News headline image
Allurion to Participate in the ROTH 4th Annual Healthcare Opportunities Conference
From Allurion Technologies, Inc.
Via Business Wire
News headline image
Allurion Reports Second Quarter 2025 Financial Results and Provides Business Update
From Allurion Technologies, Inc.
Via Business Wire
News headline image
Allurion to Report Second Quarter 2025 Financial Results on August 13, 2025
From Allurion Technologies, Inc.
Via Business Wire
News headline image
Allurion Announces New Strategic Direction With Increasing Focus on Low-Dose GLP-1 Combination Therapy, Muscle Mass Maintenance, and US Market Entry
From Allurion Technologies, Inc.
Via Business Wire
News headline image
Allurion Announces New Publications on Long-Term Weight Loss Results with the Allurion Program
From Allurion Technologies, Inc.
Via Business Wire
News headline image
Allurion Announces Strategic Distribution Partnership with Minogue Medical in Canada to Pioneer New Approach Focused on Metabolically Healthy Weight Loss
From Allurion Technologies, Inc.
Via Business Wire
News headline image
Allurion Announces Submission of PMA to FDA and Additional Analyses From Pivotal AUDACITY Study That Meet Both Endpoints
From Allurion Technologies, Inc.
Via Business Wire
News headline image
Allurion Announces Findings from New Studies on Muscle Mass Maintenance in Nearly 20,000 Patients and Four-Year Weight Loss Outcomes at the 2025 Annual Meeting of the ASMBS
From Allurion Technologies, Inc.
Via Business Wire
News headline image
Allurion to Present at Jefferies Global Healthcare Conference
From Allurion Technologies, Inc.
Via Business Wire
News headline image
Allurion Presents Data on Increasing Muscle Mass and Decreasing Fat Mass in Patients Treated With the Allurion Program
From Allurion Technologies, Inc.
Via Business Wire
News headline image
Money Movers: HIT, SEPN, ALUR, LUCY, PRSO – Biotech, Healthcare, AI & Weight Loss Innovators Lead Momentum Surge – More Stocks Inside
Via AB Newswire
Topics Artificial Intelligence
News headline image
Allurion Reports First Quarter 2025 Financial Results and Provides Business Update
From Allurion Technologies, Inc.
Via Business Wire
News headline image
Allurion Presents Data on the Allurion Balloon and AI-Powered Virtual Care Suite with and without GLP-1s to Optimize Muscle Mass and Increase Weight Loss
From Allurion Technologies, Inc.
Via Business Wire
News headline image
Allurion to Report First Quarter 2025 Financial Results on May 14, 2025
From Allurion Technologies, Inc.
Via Business Wire
News headline image
Allurion Announces Postponement of Special Meeting of Stockholders
From Allurion Technologies, Inc.
Via Business Wire
News headline image
Allurion Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
From Allurion Technologies, Inc.
Via Business Wire
News headline image
Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence
From Allurion Technologies, Inc.
Via Business Wire
News headline image
Allurion to Report Fourth Quarter 2024 Financial Results on March 26, 2025
From Allurion Technologies, Inc.
Via Business Wire
News headline image
Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity
From Allurion Technologies, Inc.
Via Business Wire
News headline image
Allurion to Participate in Upcoming Investor Conferences
From Allurion Technologies, Inc.
Via Business Wire
News headline image
Allurion Announces Closing of Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline
From Allurion Technologies, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.